588679-10-1

Basic information

• Product Name: ethyl 2-(4-bromo-2-chlorophenoxy)acetate
• Synonyms: ethyl 2-(4-bromo-2-chlorophenoxy)acetate;Ethyl 2-(4-Bromo-2-Chlorophenoxy)Acetate(WX633133)
• CAS NO: 588679-10-1
• Molecular Formula: C₁₀H₁₀BrClO₃
• Molecular Weight: 293.5416
• Mol File: 588679-10-1.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 2-(4-bromo-2-chlorophenoxy)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-(4-bromo-2-chlorophenoxy)acetate(588679-10-1)
• EPA Substance Registry System: ethyl 2-(4-bromo-2-chlorophenoxy)acetate(588679-10-1)

Safety Data

• Hazardous Substances Data: 588679-10-1(Hazardous Substances Data)

Upstream product

• 3964-56-5 4-bromo-2-chlorophenol 
• 105-39-5 chloroacetic acid ethyl ester 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 497081-40-0 2-(4'-bromo-2'-chlorophenoxy)-N-(4'-sulfamoylphenyl)acetamide 
• 587841-73-4 2-(4-Bromo-2-chlorophenoxy)-N-[[[4-[[(4,6-dimethyl-2-pyrimidinyl)amino]sulfonyl]phenyl]amino]thioxomethyl]acetamide 
• 1449004-69-6 2-(4-bromo-2-chlorophenoxy)-N-(3-(N-(N-carbobenzoxy-L-leucyl)-sulfamoyl)phenylcarbamothioyl)acetamide 
• 1449004-68-5 2-(4-bromo-2-chlorophenoxy)-N-(3-(N-(N-carbobenzoxy-L-phenylalanyl)sulfamoyl)phenylcarbamothioyl)acetamide 
• 1449004-67-4 2-(4-bromo-2-chlorophenoxy)-N-(4-(N-(N-carbobenzoxy-Lisoleucyl)sulfamoyl)phenylcarbamothioyl)acetamide 
• 1449004-66-3 2-(4-bromo-2-chlorophenoxy)-N-(4-(N-(N-tert-butoxycarbonyl-Lleucyl)sulfamoyl)phenylcarbamothioyl)acetamide 
• 1449004-65-2 N-(4-(N-(N-carbobenzoxy-(L-leucyl))-sulfamoyl)phenylcarbamothioyl)-2-(4-bromo-2-chlorophenoxy)acetamide 
• 1449004-64-1 N-(4-(N-(L-leucyl)sulfamoyl)-phenylcarbamothioyl)-2-(4-bromo-2-chlorophenoxy) acetamide 
• 1449004-38-9 2-(4-bromo-2-chlorophenoxy)-N-(4-(N-(N-carbobenzoxy-Ltryptophanyl)sulfamoyl)phenylcarbamothioyl)acetamide 
• 1449004-37-8 2-(4-bromo-2-chlorophenoxy)-N-(4-(N-(N-carbobenzoxy-L-3-(4-nitrophenyl)alanyl)sulfamoyl)phenylcarbamothioyl)acetamide 
• 1449004-36-7 2-(4-bromo-2-chlorophenoxy)-N-(4-(N-(N-carbobenzoxy-Lphenylalanyl)sulfamoyl)phenylcarbamothioyl)acetamide 
• 1449004-35-6 2-(4-bromo-2-chlorophenoxy)-N-(4-(N-(N-tert-butoxycarbonyl-L-(2-phenyl)glycyl)sulfamoyl)phenylcarbamothioyl)acetamide 
• 1449004-34-5 (S)-2-(4-bromo-2-chlorophenoxy)-N-(4-(N-(N-carbobenzoxy-2-(4-acetoxyphenyl)glycyl)sulfamoyl)phenylcarbamothioyl)acetamide 
• 1449004-33-4 2-(4-bromo-2-chlorophenoxy)-N-(4-(N-(N-carbobenzoxy-2-phenylglycyl)sulfamoyl)phenylcarbamothioyl)acetamide 

Relevant articles and documents

Discovery, synthesis and biological characterization of a series of: N -(1-(1,1-dioxidotetrahydrothiophen-3-yl)-3-methyl-1 H -pyrazol-5-yl)acetamide ethers as novel GIRK1/2 potassium channel activators

The present study describes the discovery and characterization of a series of N-(1-(1,1-dioxidotetrahydrothiophen-3-yl)-3-methyl-1H-pyrazol-5-yl)acetamide ethers as G protein-gated inwardly-rectifying potassium (GIRK) channel activators. From our previous lead optimization efforts, we have identified a new ether-based scaffold and paired this with a novel sulfone-based head group to identify a potent and selective GIRK1/2 activator. In addition, we evaluated the compounds in tier 1 DMPK assays and have identified compounds that display nanomolar potency as GIRK1/2 activators with improved metabolic stability over the prototypical urea-based compounds. This journal is

Cdc42 Inhibitor and Uses Thereof

Compounds which inhibit the small G protein Rho GTPase cell division cycle protein Cdc42 are provided. Morphological analyses of filopodia, western blots of Ccd42 phosphorylation, and effects on cellular wound healing and on growth cone formation all demo

COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT

Disclosed herein are an HIF-1 inhibitor, a method for the preparation thereof, and a pharmaceutical composition comprising the same as an active ingredient. The HIF-1 inhibitor shows anticancer activity thanks to the inhibition activity against HIF-1, a transcription factor which plays an important role in the growth and metastasis of cancer, but not to general cytotoxicity. Thus, the HIF-inhibitor and a pharmaceutically acceptable salt thereof can be used as a therapeutic for various cancers such as liver cancer; stomach cancer and breast cancer. Also, the compound having inhibition activity against HIF-1 is useful in the treatment of diabetic retinopathy and arthritis, which are aggravated by HIF-1-mediated VEGF expression.